Business
Inflation Proves That Cannabis Branding Is Irrelevant Once Again – Consumers Choose Quantity over Quality in New Sales Trends
Branding in the marijuana industry has always been a myth, now consumers are proving it once again
At the start of the ongoing inflation and recession, many cannabis skeptics and stakeholders believed that the industry could suffer significantly at the peak of inflation. They were wrong! Despite the increased difficulty of living, American marijuana users consume the same quantity of marijuana or more than they did a year earlier. This is supported by a recent poll that independent market research firm Pollfish performed on behalf of Jushi Holdings Inc.
Although most stoners and medical users tend to purchase less expensive cannabis products to combat inflation, the reason for this rise in demand is still unclear. The newly released World Drug Report 2022 by the UN Office on Drugs and Crime (UNODC) argues that the increased usage of cannabis in North America as a result of legalization, the COVID-19 epidemic, and associated lockdowns is the primary reason why demand is high. In a different analysis, the Brightfield Group predicted that this growth might cause the national recreational market to reach $30.6 billion by 2025.
Cannabis consumption during ongoing inflation
The majority (52%) of the 1000 Americans aged 21 and older who participated in the Pollfish study about cannabis usage, legalization, holiday shopping, and consumption habits revealed that they are still smoking roughly the same amount of marijuana as they had a year earlier. Additionally, approximately a quarter (24%) reported they were consuming cannabis even more than they were the year before, according to Forbes. The study explicitly discovered a shift in consumer interest from branding or strain type to THC levels and price ranges. Julian Scaff, head of Jushi experience and associate professor at ArtCenter College of Design, oversaw the study.
Consumers are buying more flower, which have a 6% market share, compared to last year, and fewer pre-rolls, edibles, tablets, tinctures, and liquids. The researchers claim that since manufactured goods are frequently more expensive than flowers, prices probably drive this trend. And strangely, even though most cannabis consumers are switching to less costly options, on average, 29% of consumers are spending more, while about 44% are paying the same on marijuana as they did a year ago.
In general, the majority spend between $50 and $100 per month (35%), while 23% spend between $100 and $150 per month. The trends come as Americans continue to feel economic pressure, with core inflation hitting a 40-year high in September, according to another poll via Reuters/Ipsos.
While every consumer-facing survey ever done on marijuana users show that cannabis branding is a myth, many marketers whose paychecks rely on producing cool logos and boxes refuse to acknowledge that data that shows consumers do not remember what they bought, how big the box was, what colors were on the box, etc. They only remember the price they paid, the effect they got, and how far or long it look to get the product. Why doesn’t branding work for weed? Cannabis is a plant that can grow in 8 to 12 weeks, indoors or out, it is a commodity like tomatoes, kale, and broccoli. Unless your branding can create a better broccoli, the consumer will go to the lower price product that gets the job done. There is a reason Bud and Bud Light are the #1 and #2 selling beers in America. They are cheap, get the desired job done for the consumer, and they are easily accessible everywhere.
Cannabis Consumption Prior to the Recession
According to statistics, sixteen percent of Americans actively use marijuana, which is statistically comparable to the 12% to 13% percentages Gallup tallied between 2016 and 2021. Since 2013, when Gallup first posed the question, the number of Americans who report using marijuana has more than doubled. According to a different survey, 48% of adults say they have at least tried marijuana, which is in line with the 43% to 49% range seen since 2015.
These statistics come from Gallup’s July 5-26, 2021, annual Consumption Habits survey. Similar percentages of men (18%) and women (14%) also revealed they use cannabis; however, smoking rates vary among other demographic groups. For more context, Three out of ten young adults (ages 18 to 34) report using marijuana, compared to roughly half of adults (ages 35 to 54) and even less of adults (ages 55 and above) who report using the drug, Students with a college degree (12%) have a similar likelihood of smoking marijuana as those without one (18%), Republicans (12%) and Democrats (20%) are both more likely than independents (17%) to report using marijuana.
Vapes and pre-roll joints are some of the most popular cannabis items available at dispensaries. According to Headset, vape pens generated a lot of cash for cannabis shops between 2020 and 2021, ranking as the second-largest category by revenue in the U.S. market. Vapes came in closely behind flowers in 2021 retail sales in California, Colorado, Michigan, Oregon, and Washington, bringing in nearly $2.6 billion (or roughly $8 per cannabis consumer in the U.S.).
Cannabis Stays Recession-Proof
According to industry experts, most cannabis users are as devoted to their drug as they are to other necessities like toilet paper, prescription medications, and alcohol. Former Sacramento, California, cannabis regulator Joe Devlin, then senior vice president with Ikänik Farms, based in the state’s capital city, stated in 2020 that he thought the marijuana industry was “relatively recession-proof” primarily because it had been categorized alongside spirits and tobacco. According to him, using cannabis is a way for people to unwind and treat themselves. Additionally, they are not likely to completely erase it from their budgets.
Legalization of Cannabis In The United States
Marijuana is prohibited under federal law, but in recent years, many states have authorized the herb for medical or recreational purposes. The evolving legal situation corresponds with the tremendous growth in public support for legalization, which most Americans support. The U.S. Congress is working to pass significant cannabis legislation at the federal level. In April 2022, the House of Representatives approved legislation that would make cannabis legal across the country. President Biden has also taken steps that might lead to the federal decriminalization of marijuana.
As a result of the absence of federal legislation, cannabis firms in states where recreational sales are permitted still lack access to institutional financing and standard banking services. Such limitations would be lifted by a federal law known as the Secure and Fair Enforcement Banking Act (SAFE), which has passed the House multiple times but has yet to be approved by the Senate.
Bottom Line
Americans have had to deal with historically high inflation, the Federal Reserve raising interest rates quickly, a decline in housing activity, high unemployment, and sluggish economic growth over the past year. Although cannabis customers in the United States are still getting used to inflationary pressures, which are relatively new to North America but quite typical elsewhere in the world, they have refused to let it significantly affect their cannabis needs and habits. It is worth noting that most dispensaries have begun stocking cheap and affordable products to maintain the demand and ensure customers continue accessing legal cannabis.
Business
New Mexico cannabis operator fined, loses license for alleged BioTrack fraud
New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.
The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.
Golden Roots operates the The Cannabis Revolution Dispensary.
The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.
The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.
Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.
After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.
In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.
The company requested a hearing, which the regulator scheduled for Sept. 1.
At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.
Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.
Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.
The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:
- Regulators alleged in August that Albuquerque dispensary Sawmill Sweet Leaf sold out-of-state products and didn’t have a license for extraction.
- Paradise Exotics Distro lost its license in July after regulators alleged the company sold products made in California.
Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.
Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/
Business
Marijuana companies suing US attorney general in federal prohibition challenge
Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.
According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”
Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.
The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”
The companies want the case to go before the U.S. Supreme Court.
They hired prominent law firm Boies Schiller Flexner to represent them.
The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.
Similar challenges to the federal Controlled Substances Act (CSA) have failed.
One such challenge led to a landmark Supreme Court decision in 2005.
In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.
In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.
Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.
“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.
“Moreover, the facts on which those precedents are based are no longer true.”
Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”
While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.
“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”
Business
Alabama to make another attempt Dec. 1 to award medical cannabis licenses
Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.
The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).
Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.
Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.
That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.
Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.
Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.
A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.
Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/
-
Business1 year ago
Pot Odor Does Not Justify Probable Cause for Vehicle Searches, Minnesota Court Affirms
-
Business1 year ago
New Mexico cannabis operator fined, loses license for alleged BioTrack fraud
-
Business1 year ago
Alabama to make another attempt Dec. 1 to award medical cannabis licenses
-
Business1 year ago
Washington State Pays Out $9.4 Million in Refunds Relating to Drug Convictions
-
Business1 year ago
Marijuana companies suing US attorney general in federal prohibition challenge
-
Business1 year ago
Legal Marijuana Handed A Nothing Burger From NY State
-
Business1 year ago
Can Cannabis Help Seasonal Depression
-
Blogs1 year ago
Cannabis Art Is Flourishing On Etsy